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Abstract
Background: There may be changes in cognitive function in women going through the menopause. The current
evidence remains unclear, however, whether these changes occur over and above those of general ageing. We
aimed to evaluate the potential impact of the menopause (assessed by reproductive age and hormone levels) on
cognitive function in women in mid-life accounting for the underlying effects of ageing.
Methods: The study was based on the follow up of women originally enrolled in pregnancy in a birth cohort when
resident in the South West of England, UK between 1991 and 1992. Using up to three repeated measurements in
2411 women (mean age 51 at first assessment), we modelled changes in six cognitive function domains: immediate
and delayed verbal episodic memory, working memory, processing speed, verbal intelligence and verbal fluency.
The exposures of interest were reproductive age measured as years relative to the final menstrual period (FMP),
chronological age and reproductive hormones (follicle-stimulating hormone (FSH), luteinizing hormone (LH) and
anti-Müllerian hormone (AMH)).
Results: Processing speed (− 0.21 (95% CI − 0.36 to − 0.06) standard deviation (SD) difference per 10 years since
FMP), immediate verbal episodic memory (− 0.15 (95% CI − 0.35 to 0.06)) and delayed verbal episodic memory (−
0.17 (95% CI − 0.37 to 0.03)) declined with reproductive age. Reproductive hormones were not robustly associated
with processing speed, but FSH and LH were both negatively associated with immediate (− 0.08 (95% CI − 0.13 to
− 0.02) SD difference per SD difference in hormone level) and delayed verbal episodic memory (− 0.08 (95% CI −
0.13 to − 0.03)). There was little consistent evidence of cognitive function declining with menopause in other
cognitive domains.
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Conclusions: Of the cognitive domains tested only verbal episodic memory declined both in relation to age since
the menopause and in conjunction with the reproductive hormones that reflect the menopause. This decline was
independent of normal ageing and suggests that the menopause is associated with a mild impact on this specific
domain of cognitive function.
Keywords: Menopause, Cognitive function, ALSPAC
Background
Understanding mechanisms responsible for cognitive
changes during middle age may be key to developing
treatments for the psychiatric and neurological condi-
tions that are common in older adulthood. The meno-
pause and its associated hormonal changes may be one
such mechanism. Many women report experiencing
changes in cognitive function, such as increased forget-
fulness and poor concentration, during the menopausal
transition [1]. Whether these alterations in cognitive
function reflect the transition per se and its associated
changes in reproductive hormones, or is related to
symptoms of the menopause such as disruption of sleep
by vasomotor symptoms, is unclear [2–4]. Furthermore,
if there is any such impact of menopausal changes,
whether specific aspects, i.e. ‘domains’, of cognitive func-
tion are adversely affected is uncertain (see Table 1).
Other factors that occur in mid-life such as changing
roles in family and work may also be involved. As evi-
dence suggests age-related decline in cognitive function
may start from early- to mid-40s in both women and
men [9, 10], it is possible that menopause-attributed de-
cline simply reflects chronological age-related change.
To understand whether cognitive function changes in
relation to increasing reproductive age over and above
any underlying change with chronological age requires
repeated assessments of cognitive function in women
across mid-life. Only one previous study has modelled
reproductive age and chronological age simultaneously
[11], and found evidence for a decline across years since
final menstrual period (FMP), independently of chrono-
logical age, for verbal fluency, visuospatial abilities and
episodic memory with up to three repeated measures in
193 women [11]. Other previous studies with repeated
Table 1 Summary of the measures of cognitive function used in this study and the domains that they aim to assess
Domain Test Domain description Brief description of what the test consisted of
Verbal episodic memory Immediate logic memory test A measure of ability to remember
experienced events and other familiar,
contextual information, immediately
after events.
Told a ‘story’ in a standardised way (tape
recording) then asked about key facts
immediately after the ‘story’ was completed.
Score reflects number of facts correctly
remembered [5].
Verbal episodic memory Delayed logic memory test A measure of ability to remember
experienced events and other familiar,
contextual information, after a short
delay.
As above but asked to recall key facts after
undergoing other cognitive tests. Score reflects
number of facts correctly remembered [5].
Working memory Backward digit span test A measure of ability of the ‘executive
function’ to temporarily retain and
manipulate information.
A test in which the tester says three digits
(e.g. 9-1-7) and the participants were asked to
repeat three digits backwards (i.e. 7-1-9). Score
reflects number of trials passed [6, 7].
Processing speed Digit symbol coding test A measure of the speed at which
the executive function can manipulate
information.
Participants were asked to fill in symbols
corresponding to certain numbers and given
two minutes to complete as many entries as
possible. Score reflects number of correct
entries done in allocated time [7].
Verbal intelligence Spot-the-word test A measure of language-based
general cognitive ability.
Participants were asked to identify the real
word from a pair in which one is real and
the other one is a made-up word. The score
is the number of real words correctly identified [8].
Verbal fluency Same letter word test A measure which relates both to
vocabulary as well as the speed
at which information can be retrieved.
Participants were asked to list as many
words as they could beginning with the
letter ‘C’ in 1 min. This was repeated for
the letters ‘F’ and ‘L’. The score reflects the
number of correct words beginning with
the letters that were freely recalled in the
allocated time [6].
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measurements of cognitive function studied across dif-
ferent menopausal stages suggest that verbal episodic
memory, verbal fluency and processing speed may be
impacted in peri- and post-menopause, but there is less
compelling evidence of effects on working memory [2–4,
11–13]. The studies were generally small, but in the lar-
gest study to date, processing speed, verbal memory and
working memory were tested up to four times between
ages 45 and 63 (N = 1903) [2]. These domains of cogni-
tive function were not found to differ by menopausal
stage, but the authors suggested that transitioning
through the menopause may be associated with a re-
duced ability to learn based on the lack of evidence of
improvement with practice or ‘learning’ on repeats of
the same cognitive tests.
In this study, we used rich longitudinal data to charac-
terise how cognitive function is related to reproductive
age (years since FMP) and reproductive hormones (fol-
licle-stimulating hormone (FSH), luteinizing hormone
(LH), and anti-Müllerian hormone (AMH)) as indicators
of the menopausal transition. We use FSH, LH and
AMH as biomarkers of the menopausal transition, be-
cause they show characteristic changes across the meno-
pause [14–16]. Oestrogen was not measured because it
is more variable in pre-menopause, and FSH and LH will
reflect change in oestrogen over the menopausal transi-
tion. We explored whether any change by reproductive
age was independent of changes related to chronological
ageing, test practice (‘learning’) effects and potential con-
founders. A priori we considered that showing associa-
tions of both reproductive age and reproductive
hormones with any domain of cognitive function would
provide more robust evidence of a likely impact than as-
sociations with just one of these. In secondary analyses,
we sought to replicate the analysis that menopause may
be associated with a reduced ability to learn [2].
Methods
Study participants
We used data from the mothers of the Avon Longitu-
dinal Study of Parents and Children (ALSPAC) birth co-
hort. Full details of the study have been previously
reported [17, 18]. ALSPAC enrolled 14,541 pregnancies
in the South West of England (around the city of Bristol)
with an expected delivery date between 1st April 1991
and 31st December 1992. The participating families have
been followed up through to the current day [17]. Please
note that the study website (http://www.bristol.ac.uk/
alspac/researchers/our-data/) contains details of all the
data and interview guides that are available through a
fully searchable data dictionary and variable search tool.
In 2009–2011, all mothers still engaged with the study
(N = 11,264) were invited to a follow up assessment
clinic, with 4834 (43%) of invited women attending. The
participating women were older and more educated than
the original sample recruited in pregnancy [18]. A fur-
ther three follow-up assessment clinics, each successively
1 to 2 years apart, were undertaken focusing on women
who were pre-menopausal in the initial clinic and there-
fore likely to go through the menopausal transition dur-
ing the subsequent three assessments, reflecting the aim
to explore social, lifestyle, health and biological changes
as women go through the menopausal transition [19].
This study is restricted to these three later clinics in
which cognitive function tests were administered.
Figure 1 describes the participant flow into the analyses.
Women were included irrespective of whether they
changed through one or all three of the menopausal
stages of pre-, peri- and post-menopause as our primary
exposures were not these categories but reproductive
age and hormones. Women who had undergone surgical
menopause at baseline or follow up were excluded, as
were women reporting using hormone replacement ther-
apy (HRT) or hormonal contraception at baseline, so
that the focus was on changes occurring across a natural
menopause. Observations for women who reported
using HRT or hormonal contraception in follow up were
also censored at the last point before reported use. The
analysis sample consisted of 2411 women with 1386
women participating in all three assessment clinics. A
majority of the participants (97%) were White British.
Reproductive age
Women were asked a detailed set of questions about the
date of their last menstrual period and the regularity of
their menses by interview at each assessment clinic.
These questions were designed to be able to categorise
participants into Stages of Reproductive Aging Work-
shop (STRAW) categories [15]. FMP could be identified
when at least 1 year of amenorrhea had occurred since
the date of the last menstrual period. Using this infor-
mation, reproductive age was calculated retrospectively
using years since FMP and coded as zero when women
were pre-FMP. Reproductive age could not be measured
before FMP due to the relatively small number of
women having their FMP during the study follow up. A
binary variable on whether the woman had reached their
FMP was also determined for each assessment clinic.
Hormones
Levels of FSH, LH, and AMH were assessed from fasting
samples in women at the three assessment clinics with-
out restrictions on which day in the menstrual cycle the
participants were at the time of blood sampling. Women
were instructed to fast overnight or for at least 8 h be-
fore the clinic visit, and the blood samples were proc-
essed within 4 h and stored at − 80 °C until thawed for
hormonal analyses (with no previous thaw-freeze cycles).
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Serum FSH, LH and AMH were measured with a Roche
Elecsys modular analytics Cobas e411 using an electro-
chemiluminescence immunoassay. The AMH assay used
was the fully automated Elecsys AMH Plus immuno-
assay from Roche Diagnostics [20].
Menopausal stage
STRAW criteria [15], using the date of the last men-
strual period and the regularity of menses, were used to
categorise women into menopausal stages [19]. In this
study, we condensed the more detailed categories into
(i) pre-menopausal (reproductive, STRAW categories − 5
to -3a), (ii) peri-menopausal (menopause transition and
first year post-menopause, STRAW − 2, − 1 and + 1a)
and (iii) post-menopausal (from second year post-
menopause, STRAW +1b to + 2).
Cognitive tests
Six different cognitive tests were administered at each of
the three assessment clinics according to a standardised
protocol to assess specific domains of cognitive function
(see Table 1). Higher scores on each test reflect better
cognitive function.
Confounders
We adjusted for (1) educational attainment, as defined
by the highest attained qualification (i) Certificate of
Secondary Education (CSE), ordinary- (O-) level or voca-
tional certificate (qualifications usually obtained at age
16, the UK minimum school leaving age when these
women were at school), (ii) Advanced A-level (usually
taken at 18 years) or (iii) university degree, and (2) age at
first pregnancy. Information on both were obtained by
questionnaire when the women were first recruited.
As the period between each of the assessments was 1
to 2 years, practice effects may have occurred in cogni-
tive test performance. That is, performance may have
improved, or an age-related decline be somewhat
masked, as a result of familiarity with the test. We
accounted for this in our analyses with a (3) time-
varying continuous variable detailing the number of pre-
vious testing occasions. In addition, we adjusted for (4)
the fieldworker who had administered the test to reduce
any potential variation in performance related to how
the tests were administered.
Statistical methods
Descriptive statistics were calculated and cognitive test
scores at the first assessment clinic were examined by
menopausal stage using analysis of variance.
Main analyses
Full details of the strategy for the main analyses, includ-
ing details of all multilevel models, are provided in Sup-
plementary Text (Additional file 1). Briefly, we used
multilevel linear regression models to examine: (i)
change in cognitive function domains by reproductive
age (years since FMP) and chronological age and
Fig. 1 Participant flow into eligible and analysis groups, 2011–2015
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compare the contributions of each of these and (ii)
the association of standardised LH, FSH and AMH
levels (using mean and standard deviation (SD) from
first assessment clinic, having replaced undetectable
LH and AMH levels with 0.1 mIU/ml and 0.01 ng/ml
respectively) with cognitive function. Multilevel
models allow all women with at least one cognitive
function assessment to be included in analyses under
a missing-at-random (MAR) assumption and take ac-
count of the correlation between repeated measure-
ments. As we only had up to three measurements in
each woman, we had to assume any change with re-
productive or chronological age or association with
hormones were linear. We modelled each cognitive
function domain in SD units, using the mean from
the first assessment clinic and the estimated
between-individual SD derived from the fully ad-
justed model.
The Bayesian Information Criteria (BIC) was used
to assess and compare how reproductive and chrono-
logical age explained variation in cognitive function.
The main models were adjusted for fieldworker ef-
fects, practice effects, chronological age, education
and age at first pregnancy. To assess associations of
reproductive hormones (FSH, LH and AMH) with
cognitive function, each was included as a time-
varying exposure in separate models, with the results
reflecting the difference in cognitive function between
women with one SD difference in hormone level at
any given age.
Lastly, we studied differences in the extent of improve-
ment in cognitive function by practice at pre-, peri- and
post-menopause. We tested whether the interaction be-
tween practice effects (with a random slope) and meno-
pausal stage improved model fit in a model including
chronological age, education and age at first pregnancy
using log likelihood tests.
Sensitivity analyses
We compared baseline cognitive function scores by the
duration of follow-up time available to examine whether
results may have been biased by loss to follow-up. We
also repeated the main analyses in a sample restricted to
women who participated in all three clinics. All analyses
were conducted in Stata 15.1 (StataCorp, Texas, US) and
MLwIN version 3.01 using command ‘runmlwin’ [21].
Ethical approval
Ethical approval for the data collection was obtained from
the ALSPAC Ethics and Law Committee and the Local
National Health Service Research Ethics Committees. In-
formed written consent for the use of data collected via
questionnaires and clinics was obtained from participants.
Consent for biological samples has been collected in ac-
cordance with the Human Tissue Act (2004).
Results
Participant characteristics
Table 2 details the characteristics of the participants by
assessment clinic. The mean age of the women at the
first assessment was 51 years (SD 4.4, Table 2), and the
average age at menopause of the women was 50 (SD
3.8). The age range of women during the study was be-
tween 36 and 66 years. 38% of women were identified as
pre-menopausal at the first assessment, decreasing to
20% by the last. With the exception of verbal
intelligence, mean performance on all cognitive tests in-
creased modestly across the three assessments.
Table 3 shows cognitive test scores by menopausal
stage in women participating in the first assessment
clinic. There were small differences in mean levels of
processing, verbal intelligence and verbal fluency
across categories of menopausal stage. For processing
speed levels were highest in pre-menopausal women
(mean 82.5, SD 13.8), intermediate in those who were
peri-menopausal (80.6, SD 13.8) and lowest in those
who were post-menopausal (78.7, SD 13.5). For verbal
intelligence and verbal fluency, the direction of asso-
ciation was the opposite, with levels being lowest in
pre-menopause and highest in post-menopausal
women. Mean levels of immediate and delayed verbal
episodic memory and working memory were similar
across the menopausal stages.
Main results
Reproductive age and cognitive function
Supplementary Table 1 (Additional file 1) details the re-
sults of the different models for cognitive function by re-
productive and chronological age. These suggest that
both reproductive age and chronological age contribute
to change in cognitive function. In simpler models,
chronological age tended to have a stronger relationship
with cognitive function compared with reproductive age,
except for processing speed.
The fully adjusted associations of reproductive and
chronological age with cognitive function are pre-
sented in Fig. 2a (detailed results of different models
are shown in Supplementary Table 1, Additional file
1). Reproductive age was negatively associated with
immediate (SD difference − 0.15, 95% CI − 0.35 to
0.06) and delayed (− 0.17, 95% CI − 0.37 to 0.03) ver-
bal episodic memory and processing speed (− 0.21,
95% CI − 0.36 to − 0.06), though for the former confi-
dence intervals were wide and consistent with no dif-
ference. Working memory (0.01, 95% CI − 0.14 to
0.16), verbal intelligence (0.06, 95% CI − 0.08 to 0.21)
and verbal fluency (− 0.06, 95% CI − 0.22 to 0.09)
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changed little with reproductive age. Associations of
chronological age with cognitive function were more com-
plex, with positive associations with verbal intelligence
(0.28, 95% CI 0.15 to 0.41) and verbal fluency (0.16, 95%
CI 0.04 to 0.28), negative associations with both immedi-
ate (− 0.21, 95% CI − 0.42 to 0.00) and delayed (− 0.23,
95% CI − 0.44 to − 0.03) verbal episodic memory and pro-
cessing speed (− 0.37, 95% CI − 0.51 to − 0.23), but for
former only before FMP, and a largely null association
with working memory (− 0.04, 95% CI − 0.21 to 0.12).
Reproductive hormones and cognitive outcomes
The results for the fully adjusted associations of FSH,
LH and AMH with cognitive function are shown in
Fig. 3a (detailed results of different models are shown in
Supplementary Table 2, Additional file 1). FSH and LH,
which increase around menopause, were negatively asso-
ciated with immediate (− 0.08, 95% CI − 0.13 to − 0.02,
and − 0.08, 95% CI − 0.13 to − 0.03, respectively) and de-
layed (− 0.04, 95% CI − 0.09 to 0.01, and − 0.05, 95% CI
− 0.10 to 0.00, respectively) verbal episodic memory, and
Table 3 Cognitive function at the first assessment clinic by menopausal stage (N = 1894–1909)
Mean (SD) score by menopausal stage P-value*
Pre-menopause Peri-menopause Post-menopause
Immediate verbal episodic memory 15.6 (3.4) 15.7 (3.6) 15.5 (3.7) 0.41
Delayed verbal episodic memory 14.4 (3.6) 14.5 (3.9) 14.3 (3.9) 0.55
Working memory 7.0 (2.4) 7.2 (2.3) 7.2 (2.4) 0.11
Processing speed 82.5 (13.8) 80.6 (13.8) 78.7 (13.5) < 0.001
Verbal intelligence 42.3 (7.7) 44.6 (7.4) 45.7 (7.4) < 0.001
Verbal fluency 42.1 (11.9) 43.8 (11.8) 43.8 (12.3) 0.01
*P-value from an ANOVA test for trend. Cognitive test scores by menopausal stage in women participating in the first assessment clinic
Table 2 Characteristics of participants at the three assessment clinics (N = 2411)
Clinic 1 Clinic 2 Clinic 3
N = 1981 N = 2050 N = 1981
Age, mean (SD) 50.9 (4.4) 52.2 (4.4) 53.3 (4.4)
Years since final menstrual period, mean (SD) 1.90 (3.4) 2.54 (3.8) 3.19 (4.3)
Menopausal stage
Pre-menopause, N (%) 749 (38%) 544 (27%) 394 (20%)
Peri-menopause, N (%) 532 (27%) 532 (26%) 479 (24%)
Post-menopause, N (%) 659 (33%) 807 (39%) 925 (47%)
Unable to determine, N (%) 41 (2%) 167 (8%) 183 (9%)
Cognitive function score
Immediate verbal episodic memory, mean (SD), sample range 3–25 15.6 (3.6) 16.0 (3.3) 16.6 (3.3)
Delayed verbal episodic memory, mean (SD), sample range 0–25 14.4 (3.8) 15.0 (3.6) 15.9 (3.5)
Working memory, mean (SD), sample range 2–14 7.1 (2.4) 7.2 (2.3) 7.4 (2.3)
Processing speed, mean (SD), sample range 10–133 80.7 (13.8) 82.8 (13.6) 83.7 (14.0)
Verbal intelligence, mean (SD), sample range 0–60 44.1 (7.7) 44.2 (7.3) 44.2 (7.4)
Verbal fluency, mean (SD), sample range 0–98 43.2 (12.0) 45.1 (12.5) 45.8 (12.6)
Education
CSE / Vocational / O-level, N (%) 925 (47%) 977 (48%) 930 (47%)
A-level, N (%) 597 (30%) 618 (30%) 599 (30%)
Degree, N (%) 459 (23%) 455 (22%) 452 (23%)
Age at first pregnancy, mean (SD) 26.7 (4.7) 26.6 (4.8) 26.6 (4.7)
Reproductive hormones
AMH (ng/ml), median (IQR) 0.01 (0.01–0.17) 0.01 (0.01–0.08) 0.01 (0.01–0.03)
FSH (mIU/ml), median (IQR) 35.9 (7.4–74.2) 58.0 (11.7–87.9) 63.8 (18.7–88.9)
LH (mIU/ml), median (IQR) 24.4 (7.3–40.0) 31.5 (10.6–44.0) 31.8 (15.4–43.2)
AMH anti-Müllerian hormone, FSH follicle-stimulating hormone, IQR interquartile range, LH luteinizing hormone, SD standard deviation
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FSH was positively associated with processing speed
(0.04, 95% CI 0.00 to 0.07).
Sensitivity analysis
Women who were lost to follow up had lower baseline
scores on most of the tests, but notably baseline immedi-
ate and delayed verbal episodic memory scores did not
differ by loss to follow up (Supplementary Tables 3 and 4,
Additional file 1). When we restricted analyses to women
who participated in all three assessment clinics, the asso-
ciations of reproductive age with cognitive function
were similar to those of the main analyses (Fig. 2b
and Supplementary Table 5, Additional file 1).
However, in these analyses there was a stronger de-
crease in delayed verbal episodic memory (− 0.30, 95%
CI − 0.56 to − 0.04) and verbal fluency (− 0.17, 95%
CI − 0.37 to 0.02) with increasing reproductive age.
Similarly, associations of reproductive hormones with
cognitive function in the restricted sample of women
with data from all three assessment clinics were
broadly similar to the main analyses (Fig. 3b and Sup-
plementary Table 6, Additional file 1).
Secondary analyses: differential practice effects
Table 4 presents results for differential practice effects in
the main analysis participants. There was statistical
Fig. 2 Difference in standardised cognitive function by 10 years greater reproductive and chronological age. a Main analyses including all women
with at least one measure of cognitive function (N = 2402–2408). b Sensitivity analyses restricted to women with measures of cognitive function at all
three time points (N = 1385–1386). Note: Reproductive age is measured as years since final menstrual period (FMP) and chronological age is centred at
age 50 and in interaction with whether the observation is before and after FMP. Analyses adjusted for practice effects (baseline assuming no practice
effects), fieldworker effects, education (baseline CSE/vocational/O-level) and age at first pregnancy (centred at 26)
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support for a practice effect on processing speed, such
that peri-menopausal women had lower mean scores at
their first assessment (SD difference − 0.02, 95% CI −
0.13 to 0.08), but a slightly greater improvement by
practice than pre-menopausal women (interaction term
0.07, 95% CI − 0.01 to 0.15) (Pinteraction = 0.0044). For im-
mediate (− 0.09, 95% CI − 0.24 to 0.06) and delayed (−
0.14, 95% CI − 0.29 to 0.01) verbal episodic memory,
post-menopausal women had lower baseline scores than
pre-menopausal women but a greater improvement in
scores with repeated testing (interaction terms 0.09, 95%
CI 0.00 to 0.18, and 0.09, 95% CI 0.01 to 0.18, respect-
ively), though there was no strong statistical support for
an interaction (Pinteraction = 0.0581 and 0.1119, respect-
ively). For other outcomes, change with practice was
similar across the menopausal stages.
Discussion
Main findings
After taking account of chronological age, learning
effects and socioeconomic confounding, we found
that the menopause, assessed by reproductive ageing
and hormones, had little impact on most cognitive
domains, with the exception of immediate and de-
layed verbal episodic memory. If the menopause has
an adverse effect on cognition above and beyond
Fig. 3 Difference in standardised cognitive function by standardised levels of anti-Müllerian, follicle-stimulating and luteinizing hormone. a Main
analyses including all women with at least one measure of cognitive function (N = 2209–2213). b Sensitivity analyses restricted to women with
measures of cognitive function at all three time points (N = 1348). Note: AMH: anti-Müllerian hormone, FSH: follicle-stimulating hormone, LH:
luteinizing hormone. Analyses are adjusted for age (centred at 50), practice effects (baseline assuming no practice effects), fieldworker effects,
education (baseline CSE/vocational/O-level) and age at first pregnancy (centred at 26)
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chronological age, we might have expected consistent
results for all outcomes and consistency between re-
productive age and hormones. However, we found
consistency between reproductive age and reproduct-
ive hormones only for the two verbal episodic mem-
ory tests, providing some evidence that that this
cognitive domain may be influenced modestly by the
menopause, whilst highlighting that most aspects of
cognitive function were not.
In order to give a sense of the size of the estimated as-
sociations of reproductive age with cognitive function,
we compared our results with those of an independent
UK study (Whitehall II) that examined ageing and cogni-
tion [10]. The decrease in verbal episodic memory by re-
productive age in our study (− 1.28% for immediate and
− 1.58% for delayed verbal episodic memory per 10 years
since FMP) were approximately half the size of equiva-
lent results by chronological age in the Whitehall II
study, in which women aged between 45 and 49 were es-
timated to have a decline of 2.5% in verbal episodic
memory (measured with a 20 word recall test) over the
next 10 years (full details of how we harmonised our re-
sults to those from Whitehall II are provided in Supple-
mentary Text and full results in Supplementary Table 7,
Additional file 1).
Study strengths and limitations
ALSPAC is one of a limited number of longitudinal
studies with in-depth assessments of cognitive function,
hormones and menstrual history in women around the
time of the menopause [2–4, 11–13], and to our know-
ledge the largest study to date with such data. It is also
perhaps the most comprehensive in accounting for po-
tential confounders. The longitudinal study design en-
abled us to observe any potential change within women
as they initially entered the menopausal transition and in
postmenopausal years, though the closely spaced testing
occasions also created practice effects. The effects of age
may also have been partly confounded by socioeconomic
resources, because older women in this study were more
likely to be mothers who had had children later, which
is generally associated with higher socioeconomic re-
sources [22]. We adjusted for education and age at first
pregnancy to control for this confounding.
Multilevel models allow all women to be included if
they have at least one measure under the assumption
that data are missing at random (i.e. that associations do
not differ in those who have fewer repeated measure-
ments). Whilst there was some evidence that cognitive
function at baseline was lower amongst those lost to fol-
low up, analyses restricted to participants with all three
repeated measurements did not differ substantively from
the main analyses, suggesting that selection bias is not a
major concern. We fit linear spline multilevel models
because cognitive function was only measured on three
occasions and fitting non-linear change with reproduct-
ive or chronological age, for example, using fractional
polynomial or other ‘smoothing’ methods, was not pos-
sible [23, 24]. Based on these results we cannot therefore
determine whether the decline in cognitive function by
reproductive age is permanent or transient. We also
could not model reproductive age before the FMP be-
cause relatively few women experienced their FMP dur-
ing the follow up (N = 164). Despite ours being one of
the largest studies to explore these associations, further
larger studies would be valuable.
We were able to look for consistency between change
in cognitive function in relation to years since the FMP
and the associations with reproductive hormones, which
has not been done previously. FSH, LH, AMH show
characteristic changes across stages of reproductive age-
ing and may be used as more precise biomarkers of re-
productive age than self-reported FMP. They also
capture changes that occur earlier in the menopausal
transition than after the FMP. Although we did not have
information on change in oestrogen in these women,
evidence from randomised control trials of HRT sug-
gests there is no major influence of HRT on cognitive
function in young post-menopausal women [25–29].
Previous studies show a mirror image of increasing
FSH and LH and decreasing oestrogen for about
2 years before and after the FMP and thereafter plat-
eauing, and FSH has been described as the ‘best clas-
sifier’ for diagnosing the natural menopause [14, 30,
31]. AMH, in turn, is a biomarker of ovarian function
and may be the most stable and accurate predictor of
time to menopause [16].
Comparisons with previous studies
Our finding of a decrease in immediate and delayed ver-
bal episodic memory with menopause is consistent with
evidence by menopausal stage from previous longitu-
dinal studies such as analyses of the Study of Women’s
Health Across the Nation (SWAN) [2, 4, 13]. Few stud-
ies have modelled change in cognitive function by years
since FMP, but one study suggested small declines in
episodic memory, as well as verbal fluency and visuo-
spatial abilities [11]. An analysis of SWAN data demon-
strated declines in processing speed and a small decline
in delayed verbal episodic memory by years relative to
FMP, when adjusted for age at FMP and covariates (edu-
cation, financial hardship, race, language, hormone ther-
apy, oophorectomy, diabetes, menopause symptoms,
number of assessments) [32]. The decline in processing
speed that we observed by reproductive age was also
consistent with its decline across menopausal stages in
previous longitudinal studies [3, 4], although we did not
find decrements in practice effects or learning in the
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menopausal transition as suggested by an another ana-
lysis of the SWAN data [2].
The one previous observational longitudinal study of
hormonal changes and cognitive function that we are
aware of showed associations between FSH and LH and
the four administered cognitive tests (immediate and de-
layed verbal recall, processing speed, and sensorimotor
processing speed) in crude models, but not when ad-
justed for covariates (age, race, education, and BMI) in a
sample of 403 women [4]. FSH, LH and AMH show
characteristic changes during the menopause, in addition
to the variability of FSH and LH levels in the menstrual
cycle [14, 15]. In our study, overall, there was a lack of
evidence for associations of reproductive hormones with
most cognitive domains, but FSH and LH, which in-
crease during the menopause transition from around
2 years before FMP to 2 years after [14, 15], were associ-
ated with a lower score in verbal episodic memory in ad-
justed models, which is consistent with the inverse
association of reproductive age with these measure-
ments. It is possible that the associations with FSH and
LH reflect the effects of declines in oestrogen at meno-
pause, but we could not test this with the data.
Conclusions
Many women report experiencing cognitive symptoms
during menopause. In this large cohort of women, we
show that there may be a modest decline in immediate
and delayed verbal episodic memory (i.e. the ability to
remember new information, at least as measured in the
short-term) with increasing time since FMP while con-
trolling for age. It would be useful to replicate this in
further large studies and with a greater number of re-
peated measurements over a wider age span to deter-
mine whether this decline is temporary or permanent.
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